Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC.FOLD · Entity 51196 | Chief Financial Officer | January 17, 2023 | January 19, 2023 |
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | June 04, 2026 | June 08, 2026 |
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMICUS THERAPEUTICS, INC.
Report date January 17, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 398,532 |
Ending reported balance
After 2023-01-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-17 · Sale · Disposed 5,000 · Balance 405,455 F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2023-01-18 · Sale · Disposed 6,923 · Balance 398,532 F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.70. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Amylyx Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.31 · Expires 2036-06-03 | Direct | 24,372 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,372 · Balance 24,372 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Century Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2036-06-11 | Direct | 74,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 74,000 · Balance 74,000 F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2017 Filed Oct 17, 2017 01:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon stock | 7,000 | $14.25 | $99,739.50 |
DisclosureSEC source: 0001209191-17-057053 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.10 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 42,372 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-17-002456 · doc4.xml · derivative · entry 2 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,372 Underlying: Common stock · 42,372 shares Expires 2027-01-03 F1 · derivative.exercise_date: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon stock | 30,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002456 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,676 Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 2,858 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001209191-16-149319 · doc4.xml · derivative · entry 4 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,892 Underlying: Common stock · 2,858 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2016. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon stock | 2,858 | $8.00 | $22,864.00 |
DisclosureSEC source: 0001209191-16-149319 · doc4.xml · nonDerivative · entry 3 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,189 F2 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2016. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon stock | 2,858 | $8.00 | $22,864.00 |
DisclosureSEC source: 0001209191-16-149319 · doc4.xml · nonDerivative · entry 2 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2016. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:07 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon stock | 5,688 | $8.00 | $45,504.00 |
DisclosureSEC source: 0001209191-16-149319 · doc4.xml · nonDerivative · entry 1 Quimi Daphne · CIK 0001543031 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,189 F1 · kind: The sales of shares of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.